Cofetuzumab pelidotin

Cofetuzumab pelidotin (pronunciation: ko-fe-tu-zu-mab pe-li-do-tin) is a biopharmaceutical drug used in the treatment of certain types of cancer. It is a monoclonal antibody-drug conjugate (ADC) that targets the P-cadherin protein, which is overexpressed in several types of cancer.

Etymology

The name "Cofetuzumab pelidotin" is derived from the components of the drug. "Cofetuzumab" refers to the monoclonal antibody that targets P-cadherin, and "pelidotin" refers to the cytotoxic drug that is conjugated to the antibody.

Mechanism of Action

Cofetuzumab pelidotin works by binding to the P-cadherin protein on the surface of cancer cells. Once bound, the drug is internalized by the cell, where the cytotoxic drug is released. This drug then interferes with the cell's ability to divide and grow, leading to cell death.

Related Terms

• Monoclonal antibody
• P-cadherin
• Cytotoxic drug
• Biopharmaceutical
• Cancer

See Also

• Antibody-drug conjugate
• Cancer treatment
• Protein targeting

External links

• Medical encyclopedia article on Cofetuzumab pelidotin
• Wikipedia's article - Cofetuzumab pelidotin

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski